BREVIBLOC PREMIXED INJECTION DIN 02309238
Health Canada record
| Active ingredient(s) | ESMOLOL HYDROCHLORIDE 10 MG |
|---|---|
| Dosage form | Solution |
| Route | Intravenous |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | C07AB09 ESMOLOL |
| Original market date | 12-Sep-2008 |
| Current status date | 12-Sep-2008 |
| Source | Health Canada DPD |
Establishment licence of the holder
Baxter Corporation — licence 100278, currently licensed, last inspection rating C (2026-08-11).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing ESMOLOL HYDROCHLORIDE
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02188880 | BREVIBLOC INJECTION 10MG/ML | BAXTER CORPORATION | Solution | ESMOLOL HYDROCHLORIDE 10 MG | Marketed |
| 02188864 | BREVIBLOC INJECTION 250MG/ML | BAXTER CORPORATION | Liquid | ESMOLOL HYDROCHLORIDE 250 MG | Cancelled Post Market |
| 02053179 | BREVIBLOC LIQ IV 10MG/ML | OHMEDA PHARMACEUTICAL PRODUCTS, DIVISION OF BOC CANADA LIMITED | Liquid | ESMOLOL HYDROCHLORIDE 10 MG | Cancelled Post Market |
| 02053101 | BREVIBLOC LIQ IV 250MG/ML | OHMEDA PHARMACEUTICAL PRODUCTS, DIVISION OF BOC CANADA LIMITED | Liquid | ESMOLOL HYDROCHLORIDE 250 MG | Cancelled Post Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 9543 | 2008-04-25 | Supplement to a New Drug Submission (SNDS) | NEW DOSAGE FORM: NEW PRESENTATION FOR BREVIBLOC INJECTION 10MG/ML IN A 250 ML PREMIXED BAG (2500MG/250ML) |
International API supply for ESMOLOL HYDROCHLORIDE
5 active FDA Drug Master Files.
Request a quote for BREVIBLOC PREMIXED INJECTION